TRDA

Entrada Therapeutics, Inc.

Healthcare
Biotechnology
$264M market cap

Forecast run · Sep 14, 2026Upside rank 355 of 3,136

Model Signal

ForecastQ Daily Probabilities

60.1%

32.2%

42.5%

Analyst Consensus

Recommendation2.33/5 Buy

Last price$6.80

Price target$14.00

Implied move+105.9%

Analysts6

ForecastQ Portfolios

TRDA is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.